Peibin Zeng

Dr. Peibin Zeng


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Food Microbiology
Verified
Journal Article
Closed access
LZLiang Zhang
Liang Zhang
ZCZhenmin Che
Zhenmin Che
WXWeizhen Xu
Weizhen Xu
PYPeng Yue
Peng Yue
RLRui Li
Rui Li
PZPeibin Zeng
Peibin Zeng

1 April 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
TGTao Guo
Tao Guo
XDXue Dong
Xue Dong
SXShanli Xie
Shanli Xie
LZLin Zhang
Lin Zhang
PZPeibin Zeng
Peibin Zeng
Ovarian cancer is a common and complex malignancy with poor prognostic outcome. Most women with ovarian cancer are diagnosed with advanced stage disease due to a lack of effective detection strategies in the early stage. Traditional treatment with cytoreductive surgery and platinum-based combination chemotherapy has not significantly improved prognosis and 5-year survival rates are still extremely poor. Therefore, novel treatment strategies are needed to improve the treatment of ovarian cancer patients. Recent advances of next generation sequencing technologies have both confirmed previous known mutated genes and discovered novel candidate genes in ovarian cancer. In this review, we illustrate recent advances in identifying ovarian cancer gene mutations, including those of TP53, BRCA1/2, PIK3CA, and KRAS genes. In addition, we discuss advances in targeting therapies for ovarian cancer based on these mutated genes in ovarian cancer. Further, we associate between detection of mutation genes by liquid biopsy and the potential early diagnostic value in ovarian cancer.

1 September 2022 in Environmental Research
Verified
Journal Article
Closed access
HZHaojiang Zuo
Haojiang Zuo
TZTianli Zheng
Tianli Zheng
KWKunpeng Wu
Kunpeng Wu
TYTingting Yang
Tingting Yang
LWLingyao Wang
Lingyao Wang
XZXing Zhao
Xing Zhao

24 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XCXu Chen
Xu Chen
HYHaiyan Ye
Haiyan Ye
SLShilin Li
Shilin Li
BJBaihai Jiao
Baihai Jiao
JWJianqin Wu
Jianqin Wu
LCLimin Chen
Limin Chen
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus (SFTS virus, SFTSV). At present there is still no specific antiviral treatment for SFTSV; To understand which cells support SFTSV life cycle and whether SFTSV infection activates host innate immunity, four different cell lines (Vero, Hela, Huh7.5.1, and Huh7.0) were infected with SFTSV. Intracellular/extracellular viral RNA and expression of IFNα, and IFNß were detected by real-time RT- PCR following infection. To confirm the role of non-structural protein (NSs) of SFTSV in exogenous IFNα-induced Jak/STAT signaling, p-STAT1 (Western Blot), ISRE activity (Luciferase assay) and ISG expression (real-time PCR) were examined following IFNα stimulation in the presence or absence of over-expression of NSs in Hela cells. Our study showed that all the four cell lines supported SFTSV life cycle and SFTSV activated host innate immunity to produce type I IFNs in Hela cells but not in Huh7.0, Huh7.5.1 or Vero cells. NSs inhibited exogenous IFNα-induced Jak/STAT signaling as shown by decreased p-STAT1 level, suppressed ISRE activity and down-regulated ISG expression. Suppression of the exogenous Type I IFN-induced Jak/STAT signaling by NSs might be one of the mechanisms of SFTSV to evade host immune surveillance.

2 November 2011 in Transfusion
Verified
Journal Article
Closed access
PDF file
PZPeibin Zeng
Peibin Zeng
JWJingxing Wang
Jingxing Wang
YHYi Huang
Yi Huang
XGXiaoming Guo
Xiaoming Guo
JLJulin Li
Julin Li
FCfor the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), International Component
for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), International Component

16 February 2024 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PHPenggang He
Penggang He
FCFeng Cao
Feng Cao
QQQianyu Qu
Qianyu Qu
HGHuaixin Geng
Huaixin Geng
XYXin Yang
Xin Yang
GLGuangxin Luan
Guangxin Luan
Bacteriophages (phages) represent promising alternative treatments against multidrug-resistant Acinetobacter baumannii (MDRAB) infections. The application of phages as antibacterial agents is limited by their generally narrow host ranges, so changing or expanding the host ranges of phages is beneficial for phage therapy. Multiple studies have identified that phage tail fiber protein mediates the recognition and binding to the host as receptor binding protein in phage infection. However, the tail tubular-dependent host specificity of phages has not been studied well. In this study, we isolated and characterized a novel lytic phage, vB_Ab4_Hep4, specifically infecting MDRAB strains. Meanwhile, we identified a spontaneous mutant of the phage, vB_Ab4_Hep4-M, which revealed an expanded host range compared to the wild-type phage. A single mutation of G to C was detected in the gene encoding the phage tail tubular protein B and thus resulted in an aspartate to histidine change. We further demonstrated that the host range expansion of the phage mutant is driven by the spontaneous mutation of guanine to cytosine using expressed tail tubular protein B. Moreover, we established that the bacterial capsule is the receptor for phage Abp4 and Abp4-M by identifying mutant genes in phage-resistant strains. In conclusion, our study provided a detailed description of phage vB_Ab4_Hep4 and revealed the tail tubular-dependent host specificity in A. baumannii phages, which may provide new insights into extending the host ranges of phages by gene-modifying tail tubular proteins.